HPV overtakes smoking as the leading cause of oropharyngeal cancer in Ireland: experience of a head and neck surgery tertiary referral centre
Irish Journal of Medical Science (1971 -) · 2024-10 · 193 (5) · 2161-2169
DOI: 10.1007/s11845-024-03715-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Irish Journal of Medical Science (1971 -), online erschienen am 28.05.2024. Verfasst von Eoin F Cleere und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology Head and Neck Surgery, St James's Hospital, Dublin, Ireland. eoincleere@rcsi.ie. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Papillomavirus Infections, Tertiary Care Centers. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal College of Surgeons in Ireland.
Abstract (Originalsprache)
Background
Worldwide, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) caused by human papillomavirus (HPV), a sexually transmitted virus, is increasing. This increase has yet to be demonstrated in an Irish cohort.
Aims
To evaluate the number of OPSCC presentations locally, to stratify cases by HPV status and to estimate if any changes in the patient population had occurred over a 10-year period.
Methods
A STROBE-compliant, retrospective evaluation of patients with OPSCC at St James’s Hospital between 2012 and 2022 was performed. Patients with non-SCC histology, undocumented HPV status and residual or recurrent tumours were excluded.
Results
We included 294 patients with a mean age of 60.4 years (95% CI 59.2–61.5 years) and 175 (59.5%) patients had HPV+ OPSCC. The number of new OPSCC diagnoses increased from 115 patients (39.1%) between 2012 and 2016 to 179 patients (60.9%) between 2017 and 2021. This was associated with an increased proportion of HPV-linked OPSCC (50.4% 2012–2016 vs. 65.4% 2017–2021, p = 0.011). Over time, more patients had a functionally limiting comorbidity ( p = 0.011). The mean age of HPV+ OPSCC cases increased by 3.6 years ( p = 0.019). Patients with HPV+ OPSCC had greater 2-year OS (83.9% vs. 54.9%; p < 0.001) and 2-year DFS (73.5% vs. 45.6%; p < 0.001). The 2-year OS and DFS did not change over time for HPV+ or HPV− patients.
Conclusions
In our institution, the number of patients with OPSCC is increasing due to an escalation in cases associated with HPV. Population-level interventions such as vaccination programs may alter the current increase in the incidence of these tumours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology Head and Neck Surgery, St James's Hospital, Dublin, Ireland. eoincleere@rcsi.ie.
- Department of Otolaryngology Head and Neck Surgery, St James's Hospital, Dublin, Ireland.
Förderung
- Royal College of Surgeons in Ireland
Zitieren
APA
Cleere, E. F., Murphy, J., Crotty, T. J., Hintze, J. M., Timon, C. V. I., Kinsella, J., Fitzgerald, C. W. R., & Lennon, P. (2024). HPV overtakes smoking as the leading cause of oropharyngeal cancer in Ireland: experience of a head and neck surgery tertiary referral centre. Irish Journal of Medical Science (1971 -), 193(5), 2161-2169. https://doi.org/10.1007/s11845-024-03715-4
Vancouver
Cleere EF, Murphy J, Crotty TJ, Hintze JM, Timon CVI, Kinsella J, et al. HPV overtakes smoking as the leading cause of oropharyngeal cancer in Ireland: experience of a head and neck surgery tertiary referral centre. Irish Journal of Medical Science (1971 -). 2024;193(5):2161-2169. doi:10.1007/s11845-024-03715-4
BibTeX
@article{Cleere2024,
author = {Cleere, Eoin F and Murphy, Josh and Crotty, Thomas J and Hintze, Justin M and Timon, Conrad V I and Kinsella, John and Fitzgerald, Conall W R and Lennon, Paul},
title = {HPV overtakes smoking as the leading cause of oropharyngeal cancer in Ireland: experience of a head and neck surgery tertiary referral centre},
journal = {Irish Journal of Medical Science (1971 -)},
year = {2024},
volume = {193},
number = {5},
pages = {2161--2169},
doi = {10.1007/s11845-024-03715-4}
}
EUVIMED